MedPlus pauses integrated diagnostics push, pivots to smaller labs in Chennai and Bengaluru

MedPlus Health Services has shelved its integrated diagnostics model after slower-than-expected subscriber growth in Hyderabad. It will instead open standalone labs costing ₹5 crore-₹6 crore each in Chennai and Bengaluru, while retaining its target of 800 pharmacy stores by year-end.

— Source publishedMon, 21 Sept, 2026, 12:53 IST·First seen Mon, 21 Sept, 2026, 13:01 IST·Source CNBC-TV18 · Companies

What happened

MedPlus Health Services · MedPlus paused its integrated diagnostics rollout after Hyderabad subscriber growth lagged, shifting to standalone labs in Chennai and

Key facts

  • Standalone lab investment: ₹5 crore-₹6 crore each
  • Store target: 800 by year-end
  • Hyderabad diagnostics network cost: ₹110 crore-₹120 crore
  • Hyderabad addressable population: 10 million
  • Subscriber target: 5 lakh paying at least ₹1,000 annually
  • Potential annual subscriber revenue: ₹50 crore
  • Current diagnostics customers: around 2.2 lakh
  • MedPlus share price: ₹655.40
  • Market capitalisation: ₹7,869.58 crore
  • Shares declined more than 19% over the past year
  • Cold-pressed oil sales potential: over 2 lakh bottles per month

Why this matters

MedPlus’s retreat from integrated diagnostics, concierge and wellness creates partnership or acquisition openings in standalone lab networks and pharmacy-linked diagnostic services.

What to watch

  • Number and location of new lab openings in Chennai and Bengaluru versus a broader multi-city rollout.
  • Diagnostic test volumes, repeat-customer rates, home-sample-collection adoption and lab turnaround times.
  • Any introduction of pharmacy-lab bundles, membership offers, corporate packages or insurer tie-ups.
  • Progress toward 800 pharmacy stores by year-end and evidence that new stores are concentrated around lab catchments.
  • Changes in capex guidance, lease commitments, hiring for diagnostics, or renewed investment in concierge and wellness offerings.
  • Competitive responses from Apollo Diagnostics, Dr Lal PathLabs, Metropolis, Thyrocare and pharmacy chains in the two target cities.
  • Open a limited number of ₹5 crore-₹6 crore standalone diagnostic labs in Chennai and Bengaluru, likely near dense pharmacy clusters.
  • Bundle pathology tests, preventive-health packages and medicine discounts with MedPlus pharmacy loyalty programs rather than revive a full subscription-led integrated-care offering.
  • Prioritize pharmacy-store additions, cluster density, supply-chain utilization and private-label penetration to meet the 800-store target.
  • Seek partnerships with local hospitals, clinicians, insurers or corporate-health clients to improve lab sample volumes without major new service-line investment.
  • Keep paused ventures off the near-term capex plan and reassess them only after pharmacy and lab unit economics stabilize.